The discovery of mutated Calreticulin (CALR) in myeloproliferative neoplasms (MPN) has provided 2 proof of clonality, diagnostic importance, and influence on prognosis of this pathology. The 3 identification of this MPN-associated driver mutation -currently based on molecular assays-is 4 represented as a major diagnostic criterion for essential thrombocythaemia (ET), pre-fibrotic result of molecular assays. Additionally, we investigated by double staining whether expression of 1 mutated CALR can also be demonstrated on cells of the erythroid and myeloid lineage. 2 3 Material and Methods 4 Tissue Samples 5 One hundred and eighty two bone marrow biopsies from patients with myeloid neoplasms: series 6 of MPNs (n=66) and a control group of acute myeloid leukaemia (AML) (n=116) were retrieved 7 from the files of the Department of Histopathology at University College London Hospitals. The London Hospitals following the criteria of the 2008 WHO classification [1] . Approval for this study 1 0 was obtained from the National Research Ethics Service, Research Ethics Committee 4 (REC 1 1 Reference number 09/H0715/64). The bone marrow biopsies were fixed in 10% neutral buffered formalin, decalcified for six hours 1 4 using Gooding Stewart solution, processed and embedded in paraffin. Immunostaining using the 1 5 newly developed anti-human CAL2 monoclonal mouse antibody [3] was performed on bone 1 6 marrow biopsies tissue sections using the Roche-Ventana BenchMark ULTRA autostainer 1 7 (Ventana Medical Systems, Tucson, US). 1 8 The CAL2 antibody was assessed under different conditions (i.e. dilution and antigen retrieval 1 9 protocols) and the chosen dilution, which showed selective background-free reaction was 1:10. Counterstaining was performed using haematoxylin and bluing reagent from Ventana/Roche. 2 1 Slides were mounted with cover slips and air-dried. Double immuno-enzymatic labelling of biopsies' sections following the described pre-treatment 2 4 was carried out by means of the EnVision peroxidase and alkaline phosphatase kits 2 5 (DakoCytomation). Primary antibodies were incubated for 30 minutes at room temperature, and a 2 6 diaminobenzidine (DAB) substrate (DakoCytomation) was then used for detection of antibody 2 7 binding. Sections were then incubated for 30 minutes with the second antibody, and then for an 2 8 additional 30 minutes with the alkaline phosphatase EnVision kit (DakoCytomation). The second 2 9 reaction was detected by means of a Vector blue alkaline phosphatase substrate kit (Vector Mini Kit (Qiagen) was used in each assay. CAL2 immunostaining was evaluated in a total of one hundred and eighty two bone marrow 1 2 biopsies from patients with myeloid neoplasms (AML n=116, 1 3 MPNs n=66) [ Table 1 ]. Positivity was observed in twenty out of sixty-six biopsies from patients with 1 4 MPNs that included: ET n=14, chronic MPN, with MF n=3; MDS/MPN, unclassifiable n=2; MF n=1 1 5 [ Table 2 ]. In 14 of the 20 CAL2 positive cases, PCR or sequencing was performed and results 1 6 showed CALR molecular aberrations (either mutation or deletion etc.) [ Table 2 ]. 1 7 Mutated CALR expressions shown with CAL2 was mostly restricted to megakaryocytes, principally 1 8 labelling the cytoplasm and displaying a granular staining pattern [ Figure 1 ]. Even some small 1 9 CAL2 positive cells proved to be positive for CD61 thus identifying these cells as small 2 0 megakaryocytes [ Figure 2 ]. However, occasional smaller cells with round nuclei were stained by 2 1 CAL2 antibody and antibodies to myeloperoxidase or to CD71, showing that a few granulopoietic 2 2 (myeloproxidase positive) and erythropoietic (CD71 positive) cells express mutated CARL2. 2 3 None of the acute myeloid leukaemia biopsies showed a positive staining with the CAL2. Double 2 4 staining showed the CAL2 positive megakaryocytes in essential thrombocythaemia patient to co- 2 5 express GATA-1 [ Figure 1 ]. Mutations in CALR have been discovered in 50% to 80% of JAK2 and MPL wild-type patients with 2 9 Philadelphia-negative MPNs. The recent revision of WHO criteria for ET and PMF includes testing for the CALR mutation [1] . Currently, molecular methods mainly by PCR are Recently, two groups worked on developing both polyclonal and monoclonal immunohistochemical 1 stains to detect mutant CALR in bone marrow biopsies [2, 3] . 2 In our study, we confirmed the usefulness of the CAL2 monoclonal antibody in successfully 3 detecting mutant CALR in bone marrow biopsies. 4 5 We showed that the immune-reactivity of CAL2 was absolutely restricted to the presence of CALR 6 mutations, which were seen only in ET and MDS/MPN biopsies, but not in AML biopsies. There utility of the CAL2 antibody [3] and are comparable to four following studies. [5] [6] [7] [8] 1 0 1 1
Moreover, we were able to explore the lineage of few smaller cells expressing mutated CALR 1 2 described in some of those studies. Interestingly, Vannucchi et al [2] observed modest labelling by 1 3 a polyclonal antibody in myeloid and erythroid cells. However, the lineage of similar cells could not 1 4 be clarified in the first study assessing the monoclonal CAL2 antibody [3] .The results from 1 5 subsequent publications were diverse. In one 2016 study, the nine positive cases show staining in 1 6 the majority of megakaryocytes with little or no staining in any other cell types [5] .On the other 1 7 hand, Nomani et al. in the same year noted staining of small mononuclear in CALR mutant cases 1 8 [6] . By performing double immunofluorescence staining, they proposed that the small cells 1 9 appeared to be myeloid cells or blasts. Recently, Bonifacio et al [7] published unifying results 2 0 describing two different patterns of CAL2-positive staining. Pattern A is characterised by staining 2 1 of almost only megakaryocytes. In contrast, there is staining of megakaryocytes and small 2 2 elements at least partially being myeloid precursors in pattern B. 2 3 In our study, we applied double staining technique and confirmed that a subpopulation of 2 4 granulopoietic and erythropoietic cells express mutated CALR as demonstrated with the CAL2 2 5 antibody in cases of MPNs. This supports the suggestion by Nanglia et al [9] that the CALR 2 6 mutations occur in a multipotent progenitor capable of generating both myeloid and erythroid 2 7 progeny with preferential expansion of megakaryocytic cell lineage as a result of CALR mutation in 2 8 an immature hematopoietic stem cell. Additionally using double staining, we detected co-expression of GATA-1 in ET biopsies. This is 1 In conclusion, immunohistochemistry is readily available in the majority of diagnostic laboratories 2 and the detection of CALR mutations by the CAL2 antibody represents a valuable supplement to 3 traditional mutation testing and can help to facilitate the timely, appropriate selection and treatment 4 of patients with myeloproliferative neoplasms with targeted therapies. 
